EFFECTS OF THE PHYTOESTROGEN GENISTEIN ON CARDIOVASCULAR RISK FACTORS IN POSTMENOPAUSAL WOMEN
| Autor: | Francesco Squadrito, Domenico Cucinotta, Adolfo Romeo, Francesco Corrado, Nicola Frisina, Domenica Altavilla, Francesco Cancellieri, Alessandra Crisafulli, Michele Buemi, Rolando Marini, Giovanni Squadrito, Elena Bianca Adamo, Alessandra Bitto, Rosario D'Anna, Herbert Marini |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2005 |
| Předmět: |
Blood Glucose
medicine.medical_specialty Globulin medicine.medical_treatment phytoestrogen genistein Menopause Cardiovascular risk markers Osteoprotegerin Insulin resistance Receptors Cytoplasmic and Nuclear Genistein Phytoestrogens Fibrinogen Placebo Receptors Tumor Necrosis Factor chemistry.chemical_compound Sex hormone-binding globulin Double-Blind Method Sex Hormone-Binding Globulin Internal medicine Humans Insulin Medicine Glycoproteins biology business.industry Estrogen Replacement Therapy Obstetrics and Gynecology Middle Aged medicine.disease Postmenopause Treatment Outcome Endocrinology chemistry Cardiovascular Diseases biology.protein Female business Biomarkers Phytotherapy medicine.drug |
| Popis: | OBJECTIVE The phytoestrogen genistein has been shown to be the most efficacious in clinical and experimental studies. We studied whether genistein treatment affects some cardiovascular risk markers in postmenopausal women. DESIGN Sixty healthy postmenopausal women, who were 52 to 60 years of age, were enrolled in a 6-month double-blind, placebo-controlled, randomized study. After a 4-week stabilization on a standard fat-reduced diet, participants were randomly assigned to receive either genistein (n = 30; 54 mg/d) or placebo (n = 30). At baseline and after a 6-month treatment, we measured fasting glucose, insulin, insulin resistance (HOMA-IR), osteoprotegerin (OPG), fibrinogen, and sex hormone-binding globulin (SHBG). RESULTS By comparison with placebo, genistein treatment decreased significantly fasting glucose (genistein = -8.7 +/- 2.3%; placebo = 3.2 +/- 2.3%; P < 0.001), fasting insulin (genistein = -12 +/- 3.33%; placebo = 36 +/- 3.29%; P < 0.001), and HOMA-IR (genistein = -14 +/- 5.8%; placebo = 42 +/- 0.6%; P < 0.001). After genistein-treatment, fibrinogen decreased (genistein = 3.18 +/- 0.12 g/L; placebo = 3.83 +/- 0.04 g/L; P < 0.001) with respect to placebo. In the genistein group, serum OPG was lower (-2 +/- 0.3%) than in placebo (9 +/- 1.5%; P < 0.001), and serum SHBG was higher (63 +/- 3.8 nmol/L) compared with placebo (53 +/- 2.9 nmol/L; P < 0.05). CONCLUSION Our study suggests that genistein may have a favorable effect on some cardiovascular markers. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|